Login to Your Account

Financings NEWS

DUBLIN – Octimet Oncology NV raised €11.3 million (US$12 million) in a series A round for clinical development of a drug that hits c-Met, a receptor tyrosine kinase that is one of the most beguiling targets in cancer.

SAN FRANCISCO – For the first time since emerging from stealth mode last year, 2015 startup Kiniksa Pharmaceuticals disclosed its $80 million series A round and introduced the first compound in its pipeline.

Vir Biotechnology Inc., a new enterprise pursuing infectious disease therapies with immunology ideas popularized by cancer fighters, is launching under the leadership of departing Biogen Inc. CEO George Scangos.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: